Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Multiple Dose Regimens of Once-Weekly Switching to Once-Monthly MET097 in Participants With Obesity or Overweight (VESPER-3)

NCT06973720 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06973720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06973720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Multiple Dose Regimens of Once-Weekly Switching to Once-Monthly MET097 in Participants With Obesity or Overweight (VESPER-3)
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 7, 2025
Completion date
October 16, 2026
Enrollment
268 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight or obesity